Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Elyan, Benjamin M.P. and Tan, Beatrix and Lambourg, Emilie and McAllister, David A. and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. and Bell, Samira (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, 18 (5): sfaf084. ISSN 2048-8505

Elyan, Benjamin M.P. and Sullivan, Michael K. and Hedley, James and De La Mata, Nicole and Webster, Angela C. and Venugopal, Balaji and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2: 57. ISSN 2731-9377

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C. C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30. pp. 257-264. ISSN 1078-8956

Fizazi, Karim and Azad, Arun A. and Matsubara, Nobuaki and Carles, Joan and Fay, Andre P. and De Giorgi, Ugo and Joung, Jae Young and Fong, Peter C.C. and Voog, Eric and Jones, Robert J. and Shore, Neal D. and Dunshee, Curtis and Zschäbitz, Stefanie and Oldenburg, Jan and Ye, Dingwei and Lin, Xun and Healy, Cynthia G. and Di Santo, Nicola and Laird, A. Douglas and Zohren, Fabian and Agarwal, Neeraj (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30. ISSN 1078-8956